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Abstract 
A 3 d shortened course of the quinine-quinidine-cinchonin association QuinimaxO was compared to the 
usual 7 d regimen for routinely treating 462 acute uncomplicated Plasmodium falciparum malaria attacks in 
72 children under the age of 10 years in Dielmo, a holoendemic village in Senegal. 25 mgkg QuinimaxO 
salt daily, given in 3 equal doses, improved clinical status in 99.6% of the patients receiving the course and 
in all of those treated for 7 d. Even if the 3 d course did not systematically eliminate parasitaemia, reducing 
oral QuinimaxO treatment of uncomplicated malaria from 7 to 3 d did not increase the recurrence of at- 
tacks, even among the youngest children. Both the quinine sensitivity of the Senegalese strains of P. falci- 
parum and the partial acquired immunity of the children were probably responsible for the absence of any 
difference between the courses. Oral Quinimaxm for 3 d is a possible alternative regimen to chloroquine 
and sulfadoxine-pyrimethamine for treating uncomplicated malaria in highly endemic areas of Africa 
where clinical resistance to these drugs exists. 
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Introduction 
Resistance of Plasmodium falciparum to chloroquine is 
now widespread in tropical Africa. Even when chloro- 
quine produces rapid clinical improvement in most pa- 
tients, chloroquine-resistant P. falciparum is responsible 
for frequent clinical relapses (BLOLAND et al., 1993) and 
increasing malaria mortality (GREENBERG et al., 1989; 
CARME et al., 1992), which recently led one African 
country (Malawi) officially to abandon chloroquine as 
first-line therapy. Alternative drugs to chloroquine are 
scarce. Apart from their toxicity, the price of halofan- 
trine, mefloquine and other new antimalarial drugs 
makes them unaffordable for the population living in 
malaria-endemic African countries (FOSTER, 1991). 
Amodiaquine has only a limited therapeutic advantage 
over chloroquine and its use for repeated treatment is 
discouraged (WHO, 1990). The pyrimethamine-sul- 
fadoxine association is now recommended in Malawi as 
first line therapy for uncomplicated malaria. However, 
this drug is known to induce resistance rapidly and is re- 
sponsible for rare but possibly fatal reactions. Moreover 
its extensive use might induce bacterial resistance in ar- 
eas where this type of drug association is widely use for 
acute lower respiratory tract infections, another impor- 
tant cause of mortality in children. Quinine, which is 
classically reserved for the treatment of severe malaria, is 
in fact widely used in most African countries as first or 
second line treatment of uncomplicated malaria because 
of its high efficacy and relatively low cost. However the re- 
quired 3 daily doses for 7 d of the standard regimen are al- 
most never completed (FELLER-DANSOKHO et al., 1994). 
The efficacy of a 3 d oral quinine regimen has been demon- 
strated in several trials involving limited numbers of pa- 
tients (DELORON et al., 1989; JAMBOU et al., 1990; Bjöm- 
MAN et al., 1991; KREMSNER et al., 1994). This shortened 
regimen has not yet been routinely tested. As an adjunct to 
a cohort study of the natural acquisition of antimalarial im- 
munity (TRAPE et al., 1994), we compared the 3 d and 7 d 
oral regimens of Quinimaxm, an association of quinine, 
quinidine and cinchonin, for routinely treating acute un- 
complicated P. falciparum malaria in children from a 
holoendemic village in Senegal. 
Patients and Methods 
The study took place from October 1990 to May 1993 
in the village of Dielmo, Senegal, where P. falcipatum is 
holoendemic and perennially transmitted. The whole 
population was involved in a prospective study de- 
scribed elsewhere (TRAPE et al., 1994). Briefly, in order 
to identify all episodes of fever, the 247 inhabitants of 
Dielmo village were put under daily medical surveil- 
lance. At least one physician, a technician or a nurse and 
3 medical field workers were present in the village 24 h a 
day, 7 d a week. Among the population (ma1e:female sex 
ratio=0*98), 20.4% were children less than 5 years of age 
and 26.8% were children aged 5-14 years. 
Each villager was visited daily at home. Three thick 
blood films and medical examinations were made for 
each illness episode. One of the blood films was Giemsa- 
stained without previous dehaemoglobinization and ex- 
amined immediately so that a decision regarding treat- 
ment could be made; the other 2 were dehaemo- 
globinized, stained and stored. The criteria for uncom- 
plicated malaria treatment was based on age and a para- 
site:leucocyte ratio of 2 or more (TRAPE et al., 1985). 
Children under 10 years of age with uncomplicated ma- 
laria were treated with daily oral doses of 25 mg/kg 
QuinimaxB (QuinimaxB contains 71.4% quinine-resor- 
cin bichlorhydrate, 18.6% quinidine-resorcin bichlorhy- 
drate, 5% cinchonin-resorcin bichlorhydrate and 5% 
cinchonidin-resorcin bichlorhydrate) divided into 3 
equal doses administered every 8 h by a medical field 
worker or a physician. With the informed consent of 
parents, the duration of the QuinimaxB course was ran- 
domly allocated by drawing from a box containing 4 7-d 
and 6 3-d papers. In the absence of clinical and parasi- 
tological improvement after a 3 d course, it was planned 
to continue treatment for 7 d. Thexhildren were ob- 
served for 15 min after each dose; if vomiting occurred 
they were re-treated. Clinical signs and symptoms (hot 
sweats, shivering, asthenia, vomiting, diarrhoea and 
headache) were recorded and the axillary or rectal tem- 
perature was taken every 8 h for 7 d. Thick blood films 
were prepared between 3 and 10 d after the beginning of 
treatment to check its parasitological efficacy. These 
blood films were also dehaemoglobinized, stained and 
stored. All thick blood film examinations were stand- 
ardized (TRAPE, 1985). A total of 200 microscope oil-im- 
mersion objective fields was examined on each slide 
(about 0.5 p L  of blood) by the same experienced techni- 
cian at the end of the study. The parasite counts used for 
the analysis were those obtained from this independent 
examination. Finally, the malaria attacks were defined 
as fever (rectal temperature 338-5"C or axillary tempera- 
ture 338.0"C) or reported fever associated with a para- 
site:leucocyte ratio above an age-dependent pyrogenic 
threshold previously identified in this population by 
ROGIER et al. (in press) as 2.45 before the age of 12 
months, 2.7 between 12 and 23 months, 2.4 at 2 years, 
2.0 at 5 years, and 1.6 at 9 years. 
The population was asked not to use any drug without 
informing the team, and urine tests were regularly car- 
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ried out (on average once a month) to detect the pres- 
ence of antimalarial drugs, using the modified 
Saker-Solomons test (MOUNT er al., 1989). As a result, 
no antimalarial self-treatment was recorded during the - 
study period. 
For this analysis, we took into consideration the chil- 
dren aged 9 years or less who continued to live in 
Dielmo during the follow-up period (maximum absence 
10 d) and met the following criteria: (i) at least 50% of 
their life since birth spent in Dielmo or an area of high 
malaria endemicity; (ii) continued presence in the vil- 
lage or a maximum absence of 30 d during the 6 months 
preceding the study period; and (iii) continued presence 
in the village or a maximum absence of one year during 
the 3 years preceding the study. 
The clinical recovery time was calculated as the period 
between the first dose of Quinimax8 and the time when 
all symptoms disappeared, estimated as the median time 
between the last symptomatic visit and the first visit free 
of any symptom. The parasitological efficacy was as- 
sessed by the percentage of thick blood films free of 
asexual parasites between 3 and 10 d after the beginning 
of treatment. When several blood films were made, we 
took the latest into account. We recorded the frequency 
of new malaria attacks during the 60 d following the end 
of the treatment; any new malaria attacks occurring dur- 
ing the 28 d following the end of treatment were consid- 
ered to be possible recrudescences. 
We used a random-effect logistic regression model 
(STIRATELLI et al., 1984) to test proportional data, taking 
into account the interdependence of successive treat- 
ments in the same child. With this model, the estimated 
odds ratio can be considered as estimations of individual 
relative risk of treatment failure associated with the du- 
ration of the cure (ZEGER et al., 1988). It was also possi- 
ble to take into account the effect of age, season, and de- 
lay between the start of treatment and the parasitological 
examination. The odds ratios (ORs) were compared to 
one by the likelihood ratio test (HOSMER & LEMESHOW, 
1989); 95% confidence intervals (CI) were calculated. 
Results 
During the study period, 482 uncomplicated malaria 
attacks were treated with QuinimaxB. Among them, 20 
cases, 8 of 285 3-d courses and 12 of 197 7-d courses were 
excluded from the analysis either because the children 
left the village for several days during treatment or the 
medical files were incomplete. 
The analysis therefore involved 277 3-d and 185 7-d 
treatments in 72 children. In 22 cases (9 3-d and 13 7-d 
courses) the dose given was lower than the planned fig- 
ure because of vomiting without re-treatment or absence 
from the village for a few hours. In these cases, the given 
dose was on average 885% and 93.6% of the planned 
dose of the 3 d and 7 d courses, respectively. These cases 
were maintained in the analysis. 
In one case of the 3 d treatment group (0.4%), the per- 
sistence of symptoms and parasitaemia at the end of the 
course justified the prolongation of the QuinimaxB 
treatment for 7 d. For the assessment of parasitological 
efficacy, we took into consideration the positive blood 
film on the fourth day after the start of treatment. 
There was no significant difference in distribution of 
the 3 d and 7 d courses according to age, initial body 
temperature, vomiting frequency and parasite density 
before treatment (Table 1). 
In 19.9% of the 462 cases, the symptoms disappeared 
between the last visit before treatment and the start of 
the QuinimaxO course (median time: 5 h, interquartile 
interval (25-75%) 2-1 1 h). The frequency of spontane- 
ous clinical recovery was similar before both the 3 d and 
7 d courses (20.2% and 18.9%). Among the 371 children 
who were still symptomatic at the beginning of Quini- 
max8 treatment, the median clinical recovery time was 
13 h (interquartile interval (25-75%) 8-22 li). The clini- 
cal recovery rate before the twelfth hour after starting 
QuinimaxB was similar in both courses (Table 2; 
OR=0.91; 95% CI 0.57-1-46). The probability of clinical 
recovery before the twelfth hour was higher among the 
older children; it inceased by a factor of 1.3 per year of 
age (OR=1.32; 95% CI 1.16-1.5). The frequency of vom- 
Table 1. Distribution of Quinimaxa course duration 
according to age, initial body temperature, vomiting 
before treatment and initial malaria parasite density 
Duration of course 
3 d  7 6  
No. of treatments 277 185 
Age (years) 
C1 
1 
2 
3-4 
5-9 
25 (9%) 21 (11%) 
67 (24%) 39 (21%) 
52 (19%) 46 (25%) 
72 (26%) 51 (28%) 
61 (22%) 28 (15%) 
Rectal temperature "C 
~ 3 8 . 5  32 (12%) 18 (10%) 
238.5 < 39 93 (34%) 55 (30%) 
239 152 (55%) 112 (60%) 
Vomiting before treatment 83 (30%) 65 (35%) 
al? fakiparum parasites per leucocyte (geometric mean; 
Parasitaemiaa 5.98 (5.74-6.23)6*48 (6.1 1-6.76) 
95% confidence interval in parentheses). 
Table 2. Clinical and parasitological efficacy of Quini- 
max@ according to course duration 
Duration of course 
No. of treatments 
Clinical recovery time 
c12  h 
212 h 
No. cured 
No. clinically recovered 
Day 3 
before treatment 
Without parasitaemia 
With parasitaemia 
Total blood films 
Without parasitaemia 
With parasitaemia 
Total blood films 
Without parasitaemia 
With parasitaemia 
Total blood films 
start of treatment 
Yes 
No 
day 28 
Days 4-5 
Days 6-10 
No blood film 3-10 d after 
Recurrence before day 28 
No. of cases followed-up to 
277 
87 (39%) 
134 (61%) 
221 (100%) 
56 
51 (50%) 
52 (50%) 
103 (100%) 
38 (78%) 
11 (22%) 
49 (100%) 
65 (89%) 
8 (11%) 
73 (100%) 
52 
117 (48%) 
126 (52%) 
243 (100%) 
185 
59 (39%) 
91 (61%) 
150 (100%) 
35 
20 (59%) 
34 (100%) 
14 (41%) 
27 (82%) 
6 (18%) 
33 (100%) 
78 (98%) 
2 (2%) 
80 (100%) 
38 
79 (47%) 
89 (53%) 
168 (100%) 
Excluded casesa 34 17 
aAbsent for 3 or more days, or incorrect chemotherapy. 
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iring during the course was similar with both treatments 
(125% and 15.1%). 
At least one blood film was made in 372 of the 462 
cases (80.5%), 225 cases on a 3 d course and 147 on a 7 d 
course. Whatever the duration of the QuinimaxB 
course, the frequency of blood films free of parasites in- 
creased from day 3 to day 10 after the start of treatment 
(Table 2).  Taking into account the effect of the time of 
making the blood film in a logistic regression model, 
there was no significant difference in parasitological 
clearance rate between the 3 d and 7 d courses at day 3 
(OR=1.4, 95% CI 0.5-3.7) or at days 4 or 5 (OR=1.9, 
95% CI 0+6.6). However, the blood films made be- 
tween days 6 and 10 after starting treatment had a 5.9 
times higher probability of being free of parasites after a 
7 d than a 3 d course (OR=5.9, 95% CI 1.1-306). The prob- 
ability of parasitological clearance was higher among the 
older children, increasing by a factor of 1.6 per year of age 
(OR=1.6; 95% CI 1-3-2.0). There was no significant inter- 
action between the effect of age and duration of the course. 
The Figure shows a Kaplan-Meier estimate of the 
probability of occurrence of a malaria attack as a func- 
tion of time and duration of the QuinimaxO course. 
Whatever the group, the risk of a new malaria attack was 
similar during the 60 d following the end of QuinimaxO 
treatment. 
I 
O 10 20 30 40 50 60 
Days aher the end of treatment 
Figure. Incidence of new P. filciparuin malaria attacks after oral qui- 
nine-quinidine-cinchonin (Quinlmaxo) treatment according to the du- 
ration of the course: 3 d (continuous line, n=277) and 7 d (broken line, 
n=185). Dielmo, Senegal, October 1990-May 1993,72 children aged less 
than 10 years. 
In 5 1 cases, children left the village for more than 3 d 
or received unplanned antimalarial treatment (due to 
overestimation of the parasitaemia at the emergency ex- 
amination) during the 28 d following the end of the 
QuinimaxO treatment. These cases were as frequent af- 
ter a 3 d course as after a 7 d course (11.9% and 9.6%), 
and were excluded from the subsequent analysis. The 
frequency of recurrence before day 28 after the end of 
treatment was lower among the older children; it was 
decreased by a divisor of 1.2 per year of age (OR=1.22; 
95% CI 1-06-1.40). Adjusting for the effect of age and the 
seasonal malarial transmission rate by a logistic regres- 
sion model, the recurrence rate before day 28 was similar 
after both courses (Table 2; OR=0.97; 95% CI 
0.62-1.52). There was no significant interaction between 
the course duration effect and the age or seasonal trans- 
mission effects. 
Discussion 
Reducing the oral QuinimaxB treatment of uncompli- 
cated malaria from 7 to 3 d did not increase the recur- 
rence of attacks, even among the youngest children. This 
has not previously been demonstrated by trials which in- 
volved a limited number of subjects (15-35 individuals 
per .group) who were asymptomatic (BJ~RKMAN et al., 
1991) or attending an outpatient clinic (DELORON et al., 
1989; JAMBOU et al., 1990; KREMSNER et al., 1994). In 
only one of these studies (BJöRKMANet al., 1991) was the 
shortened course compared to the standard 7 d regimen. 
In nhe present study, the efficacy was assessed in routine 
practice at the population level while the absence of self 
treatment was continuously controlled, Moreover, the 
severity of symptoms and the parasite density before 
treatment, as well as the clinical recovery rate before the 
twelfth hour and the parasitological clearance rate at day 
3, testify to the similarity of both course groups before 
and after the randomization. 
The quinine-quinidinecinchonin association is 
known to be more effective in vitro than quinine alone 
(DRUILHE et al., 1988). This type of association makes 
our results difficult to compare with those assessing the 
oral efficacy of quinine given alone (BJORKMAN et al., 
1991; KREMSNER et al., 1994). Furthermore, we used a 
daily dose of 25 mglkg of the quinine-quinidine- 
cinchonin salt, which is the most widely used (FELLER- 
DA4NSOKH0 et al., 1994) and was recommended by the 
manufacturers of QuinimaxB (Sanofi). This is equiva- 
lent to 16 mgkg of quinine base daily, much less than 
the usual dosage (24-30 mg/kg quinine base) used in the 
previous studies. This could explain the low parasi- 
tological clearance rate we observed (89%) between days 
6 and 10 after the start of the 3 d treatment. This rate, on 
days 6 or 7, varied from 97% to 100% in the previous 
studies. On the other hand, we determined the parasite 
density by counting the number of parasites per 200 mi- 
croscope fields, corresponding to about 3200 leucocytes 
or 0.5 pL of blood. This represents a substantially longer 
scrutiny of each slide than that in some of the previous 
studies (DELORON et al., 1989; JAMBOU et al., 1990; 
BJORKMAN et al., 1991). Thus, the low parasitological 
clearance rates we observed are not surprising. Despite 
the lack of parasitological efficacy, the absence of any 
difference between the 3 d and 7 d courses suggests that 
new malaria attacks occurring after the end of treatment 
were most probably due to new infections. This is also 
suggested by the molecular typing of 28 P. falc$arum 
isolates collected during successive clinical malaria epi- 
sodes in 10 children treated in Dielmo by 3 d courses of 
QuinimaxO (CONTAMIN et al., in press). Comparison of 
the genotypes of the parasites showed that the parasite 
populations were different in each clinical episode. Fur- 
thermore, the 3 d QuinimaxO treatment almost always 
resulted in the disappearance of the alleles identified dur- 
ing the clinical attack. The single case in which the geno- 
types of 2 successive episodes could not be distinguished 
was a recrudescence due to obviously incomplete treat- 
ment; the delay between the 2 clinical attacks was 16 d. 
The children enrolled in the present study were in the 
process of acquiring natural protective immunity 
(ROGIER & TRAPE, 1993), resulting in a marked influ- 
ence of age on parasitological and clinical recovery. Even 
among the youngest children, not every infective bite or 
malaria infection necessarily entails the occurrence of a 
malaria attack (TRAPE et al., 1994). We also observed a 
significant proportion of spontaneous clinical recoveries 
before the start of treatment. It is obviously possible 
that, in the absence of antimalarial treatment, these re- 
coveries would have been followed by some relapses or 
intermittent fever. However, natural protective immu- 
nity may have been responsible for the absence of a dif- 
ference between the 3 d and 7 d courses, even if they did 
not invariably eliminate parasitaemia. Moreover, it  is 
not certain that eradication of infection is desirable in 
children and adults living in highly endemic areas, since 
an appreciable degree of immunity develops, and chis 
could be maintained by the stimulus of persistent infec- 
tion (WILSON, 1939). 
Investigations in vitro in Dielmo during the study pe- 
riod showed good sensitivity of l? falciparurn to quinine 
(WHO microtest of inhibition of schizont maturation: 
mean 50% inhibitory concentration [IC]= 1.02 ymol/L 
of blood medium; mean 90% IC= 4.03 pmol/L; and 
mean 100% IC=5-10 pmol/L [I. B. Bah, personal com- 
munication]). This is probably another explanation of 
the absence of difference between the 3 d and 7 d 
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courses. However, the widespread use of insufficient 
dosages is likely to encourage the development of qui- 
nine-resistant P. faleiparuni strains, which have already 
been reported in some African countries (BRANDICOURT 
et al., 1986; BRASSE UR^^ al., 1992). 
Since the other drugs are unaffordable by most of the popu- 
lations in tropical Africa, the pyrimethaminesulfadoxine 
association is the only alternative drug to chloroquine avail- 
able for treatment of chloroquine-resistant malaria. How- 
ever, it is responsible for infrequent but severe adverse reac- 
tions like Stevens-Johnson syndrome or agranulocytosis 
(SALAKO, 1984). Above all, resistance to sulfadox- 
ine-pyrimethamine has been reported in Africa and the 
rapid development of resistance to this association when i t  is 
widely used has already been observed in Asia and South 
America (BJ~RKMAN & PHILLIPS-HOWARD, 1990). 
Our observations suggest that the shortened qui- 
nine-quinidine-cinchonin regimen is safe, effective and 
well accepted in treating chloroquine-resistant P. fulci- 
paruni malaria. However, there is evidence in the litera- 
ture for an association between the wide use of quinine 
and the occurrence of blackwater fever (BRUCE-CHWATT, 
1987). It has been emphasized that African children who 
escape blackwater fever under natural conditions may 
become susceptible to this acute haemolysis when they 
are submitted to quinine treatment (MANSON-BAHR, 
1946). If the shortened oral quinine regimen is used as 
widely as chloroquine is now used in tropical Africa, 
blackwater fever could become again a fearsome threat. 
This must encourage reserving the oral use of quinine 
for malaria which is resistant to chloroquine a n d  sul- 
fadoxine-pyrimethamine. 
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